
Advantech Capital is a private equity fund focused on innovation-driven growth capital in China. The firm makes minority investments through growth equity and later-stage venture capital across TMT, e-services, and healthcare sectors.
Average disclosed round size is $84.9M (across 19 rounds with reported amounts).
Portfolio
17
Fund Size
$560M
Top Stage
Series B
Last 12 Mo
0
Team
BQ
Benjamin Qiu
Partner, Co-Head of Healthcare Investment
W(
Wenting (Julia) chen
Venture Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
22 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series B | $50M | Jun 2025 | |
| AAblaze Pharmaceuticals | Series A | $75M | Nov 2021 |
| Series A | $188M | Jun 2021 | |
| IInventisBio | Series D | $147M | Sep 2020 |
| Series C | $92M | May 2020 | |
| Series B | $10M | Apr 2020 | |
| Series A | $23.7M | Jul 2019 | |
| Series A | $100M | Nov 2018 | |
| Unknown | $300M | Oct 2018 | |
| Series B | — | Jan 2018 | |
| Series B | $93M | Oct 2017 | |
| Series B | $65M | Jan 2016 | |
| HHarbour Antibodies | Series A | $50M | Jan 2016 |
| Series C | $72.8M | Jan 2016 | |
| Unknown | $86.7M | — | |
| HHarbour Antibodies | Series B | — | — |
| Unknown | $40M | — | |
| 克克睿基因 | Series B | $60M | — |
| DData Grand | Series B | — | — |
| Series A | $15M | — | |
| AAblaze | Series A | $75M | — |
| IInventisBio | Series C | $70M | — |
Top Co-Investors
OrbiMed4 shared
Pivotal Life Sciences3 shared
Vivo Capital3 shared
SoftBank Vision Fund2 shared
venBio2 shared
Samsara BioCapital2 shared
Green Park & Golf Ventures2 shared
Atlas Venture2 shared
Legend Capital2 shared
IDG Capital2 shared
Legend Star2 shared
Walden Venture Capital2 shared
LAV2 shared
imec.xpand1 shared
Struck Capital1 shared
New Enterprise Associates1 shared
Dolby Family Ventures1 shared
Vanedge Capital1 shared
Last updated: 20 October 2026